Biomea Fusion, Inc. (BMEA): Cash & Equivalents
$55.81M
As of 2025-12-31
$34.82M
As of 2026-06-30
-20.7%
3-year compound annual growth
-2.0%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $55.81M | -4.2% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $58.28M | -67.0% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $176.87M | +58.1% | 2026-03-24, Balance as of period end |
| 2022-12-31 | $111.90M | -23.2% | 2025-03-31, Balance as of period end |
| 2021-12-31 | $145.74M | +136.2% | 2024-03-28, Balance as of period end |
| 2020-12-31 | $61.70M | n/m | 2023-03-28, Balance as of period end |
| 2019-12-31 | $239.0K | n/a | 2022-02-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $55.81M | -4.2% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $18.62M | +394.9% |
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $16.37M | -6.8% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $57.98M | -30.6% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $90.0K | -86.7% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $10.71M | -31.6% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.16M | +696.8% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $11.70M | +62.4% |
Compare BMEA, RANI, SCYX, ALXO side by side · Screen every company in Pharmaceutical Preparations ↗